biostudies-literatureUnknown41(42)Bouabdallaoui NGovernment of QuebecMontreal Heart Institute FoundationCanadian Institutes of Health Research<h4>Aims</h4>The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine.<h4>Methods and results</h4>In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was defined as the length of time between the index MI and the initiation of study medication. The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and various TTI (<3, 4-7 and >8 days) was examined using multEuropean heart journal4092-4099https://www.ebi.ac.uk/biostudies/studies/S-EPMC7700755biostudies-literatureTime-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).PMC7700755Lim PPinto FJRoubille FKoenig WKiwan GSBouabdallaoui NBerry CL'Allier PLDube MPMaggioni APDiaz RGregoire JCKouz SSamuel MBlondeau LGuertin MCBertrand OFIbrahim RMorel OTardif JCOrfanos AWaters DDLopez-Sendon JGamra HfalseTime-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).<h4>Aims</h4>The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine.<h4>Methods and results</h4>In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was defined as the length of time between the index MI and the initiation of study medication. The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and various TTI (<3, 4-7 and >8 days) was examined using mult2020-01-01T00:00:00Z2020 Nov2025-04-04T08:12:31.776Z2021-02-21T06:30:42ZS-EPMC77007553286003410.1093/eurheartj/ehaa659